Currently, there is a multitude of CD3 bispecifics with different molecular designs and binding properties in preclinical and clinical development for the treatment of liquid or solid tumors. The key safety concerns with CD3 bispecifics are excessive release of cytokines, which may translate to potentially life-threating cytokine release syndrome (CRS), target organ toxicity due to redirection of T-cells to normal tissues expressing the tumor-associated antigen (TAA) (off-tumor/on-target cytotoxicity), and, in some instances, neurotoxicity.
Full text online: https://www.tandfonline.com/doi/full/10.1080/1547691X.2020.1729902
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.